[300 Pages Report] The global digital therapeutics market is set to reach a valuation of US$ 4.8 Bn in 2022. Expanding at an impressive 24.4% CAGR over the forecast period, total sales in the digital therapeutics market will reach US$ 42.5 Bn by 2032.
| Data Points | Market Insights |
|---|---|
| Digital Therapeutics Market Value (2021) | US$ 3.9 Billion |
| Estimated Market Value (2022) | US$ 4.8 Billion |
| Projected Market Size (2032) | US$ 42.5 Billion |
| Value-based CAGR (2022 to 2032) | 24.4% |
| Market Share of Top 5 Countries | 44.4% |
Digital therapies are software solutions used in the treatment of medical disorders, and they are a new trend emerging from the rapidly progressing mobile health market. These products are similar to consumer wellness applications in which they allow consumers to have more control over their care, but with one major difference: digital therapies are focused on providing enhanced clinical outcomes.
Digital treatments can provide aid to patients at many stages of their health care journey, in addition to addressing specific medical disorders. Through the process, digital treatment (DTx) gather, synthesizes, and analyse patient data so clinical professionals can fabricate treatment options and work with the patient to wean off complications. Better outcomes and fewer medical interventions are the end results.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The digital therapeutics market grew at a CAGR of 22.0% between 2017 and 2021. The market value for global digital therapeutics held nearly 2.7% of the overall US$ 146 Bn digital health market in 2021.
The power of mobile technology to capture and hold people's attention is well known. A rising number of start-ups and established technology players are betting on that power to help people enhance their health outcomes in measurable ways.
These companies are driving software and health-care convergence in ways that can potentially change how the conventional approach of the life sciences industry, which involves both large pharma companies and medical technology or medical device companies, supports the patient health-care journey from beginning to end, spawning a new branch of medicine known as digital therapeutics.
Conventional therapies and treatments are still unable to meet unmet patient demand, while digital medicines offer the potential to do so. Enterprises that use digital therapies to close these gaps, together with substantially shorter product development timetables, may have a considerable edge over traditional life sciences companies.
Rising prevalence of preventable chronic diseases, the pressing need to regulate the cost of health care, a need for safe and accessible workarounds for the treatment of chronic and mental health diseases, a growing focus on predictive, preventative, personalised, and participatory healthcare, increasing investments in digital therapeutics are driving growth in the digital therapeutics market.
Digital therapeutics provide patient-oriented solutions through aspects such as digital behavioural interventions to devise evidence-based solutions on patient data, artificial intelligence and machine learning interventions, mobile health applications, gamification, and virtual reality. Driven by this, the market is expected to grow at a 24.4% CAGR and offer an absolute $ opportunity of nearly US$ 1 Bn between 2023 and 2022.
Numerous start-ups and existing technology companies are banking on the ability of mobile technology to help people improve their health in quantifiable ways. Manufacturers are driving software and healthcare convergence in ways that are expected to change the life sciences industry's traditional approach, which includes both large pharma and medical technology or medical device companies, supports the patient's medical journey. This has spawned a new branch of medicine known as digital therapeutics and will provide lucrative opportunities for growth over the forecast period.
Furthermore, digital therapeutics provide pharmaceutical and MedTech businesses with a low-cost approach to differentiate products, especially when compared to the research and development costs generally involved with traditional medicine or medical device.
Many businesses are refocusing their R&D efforts away from core product lines and toward revolutionary innovation. Digital medicines also have the potential to lengthen product life cycles, differentiate in-development goods, and cover market gaps that traditional medicine may not be able to fill. All these factors are expected to augment the growth in the market over the assessment period.
Principal Consultant
Wearable healthcare faces several challenges, including the fact that the data provided cannot always be used to track, diagnose, and treat health disorders due to ongoing concerns about data accuracy, consistency, and privacy.
Additionally, stakeholder awareness, acceptance, and engagement are issues for many firms that have joined the DTx industry. Most DTx solutions have entered the market with product-centric revenue models and go-to-market strategies to date.
Instead of satisfying unmet requirements of patients and other essential stakeholders across the end-to-end continuum of care, their focus has been on selling more products. As a result, the market for isolated digital point solutions is fragmented, confused, and overcrowded. There is no genuinely comprehensive, patient-centric experience to assist patients in navigating the present complex healthcare system.
As a result of the additional time and money spent on product development, the marketing and commercial sales teams are underp ressure to produce successful go-to-market plans for DTx launch, scale-up, and growth. These factors, together, induce a restrictive impact upon the growth of the overall digital therapeutics market.
“Rapid Adoption of Connective Technology-Based Medical Equipment Will Fuel Sales of Digital Therapeutics”
The U.S. dominated the North America digital therapeutics market in 2021, holding about 90.3% of the market share. As per FMI, the trend is projected to continue over the forecast period. Growth is associated with the high burden of chronic disease in the general population within the country.
Increasing incidence of gastrointestinal and central nervous system diseases is underpinning the demand for digital therapeutics. With growing adoption of telemedicine, integration and adoption of mobile health analytics in the U.S., sales are expected to increase over the forecast period.
“Growing Demand for Digital Therapeutics for Insomnia Will Augment Growth”
China is expected to account for 48.0% of the East Asia digital therapeutics market share in 2022. After the third wave of automation and digital technology integration propelled by the advent of the COVID-19 pandemic, China has established full automation solutions for medical and production facilities.
The local government has joined forces with leading DTx organisations with a joint commitment of 20 billion RMB ($32 billion) in funding support to formalise a massive DTx Industrial Park project, which is a promising indicator of Chinese DTx market progress. The project's details and funding proposal have yet to be revealed, but a newly built DTx Industrial Park in Zhejiang Province will soon serve as the DTx industrial flagship in China.
“Rising Awareness Regarding Digital Therapeutics Technology Will Boost Sales in Germany”
With a high volume of the disease burden associated with chronic ailments such as cardiovascular diseases, diabetes, and cancer, demand for digital therapeutics in Germany is anticipated to remain high. As per the report, the Germany digital therapeutics market will expand at a 20.6% CAGR over the forecast period.
In 2019, the German Parliament passed the Digital Healthcare Act (DigitaleVersorgung-Gesetz, or DVG), allowing all German doctors to prescribe digital treatments to publicly-insured patients in Germany. This has enhanced the accessibility of safe digital solutions for the treatment of chronic and mental health diseases.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
“Demand for Combination Therapy Will Gain Traction”
Based on solution, the combination therapy segment is projected to account for 68.4% of the total market share in 2022. Combination therapy with biopharmaceuticals, or “smart drugs” offers an exciting way to improve patient adherence and outcomes. Pharmaceutical companies can assist patients in improving their health outcomes by digitising drugs and utilising digital interventions to encourage their proper usage.
“Adoption of Digital Therapeutics for Disease Prevention Will Rise”
In terms of applications, the prevention segment is forecast to hold 35.8% of the total market share in 2022. For patients at risk of developing more serious ailments, digital therapeutics are routinely used as a prophylactic measure. These prevention measures provide approaches and solutions that could delay the onset of the chronic disease.
“Sales of Digital Therapeutics for Central Nervous Systems Disorders Will Boost Demand”
By indication, sales in the central nervous system disorders segment will increase at a CAGR of 29.2% over the assessment period. Several drugs that are now in use were discovered as a result of drug discovery research intended to treat central nervous system (CNS) illnesses.
However, not all drugs can relieve patients of the symptoms of their disorders, and CNS dysfunction is still a medical area with many unmet needs. Medical solutions which utilize digital technologies can address these unmet needs.
“Sales of Digital Therapeutics Direct to Patients Will Gain Momentum”
Based on distribution channel, the direct-to-patients/consumers segment will hold about 60.1% of the total market share over the forecast period. With the products being sold directly to the consumer, the availability of mobile health solutions provide customers with solutions linked to enhanced patient compliance and better clinical outcomes.
The market for digital therapeutics is a fragmented. With the emergence of start-ups and other market players, the global market is likely to witness the heavy competition. Companies are aiming to launch digital health campaigns and software solutions for a comprehensive patient care regimen. For instance:
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2017 to 2021 |
| Market Analysis | US$ Billion for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | The USA., Canada, Brazil, Mexico, Argentina, Germany, Italy, France, Spain, the UK., Russia, BENELUX, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC Countries and Turkey |
| Key Companies Covered |
|
| Key Market Segments Covered | Solution, Application, Indication, Business Model and Region |
By Solution:
By Application:
By Indication:
By Business Model:
By Region:
The global digital therapeutics market is worth US$ 4.8 Bn in 2022 and is set to expand 8.9X over the next ten years.
The global digital therapeutics market is expected to reach US$ 42.5 Bn by the end of 2032, with sales revenue expected to register a 24.4% CAGR.
Some of the significant trends in this market are the reimagined regulatory pathway for software as a medical device (SaMD) products, the rising adoption of medical technology, and the global prevalence of chronic and mental diseases.
Canada, the U.S., France, the U.K., and Italy are expected to drive demand for global digital therapeutics products.
The U.S. is one of the key markets for global digital therapeutics, accounting for about 86.2% of the overall North American market during the forecast period.
The U.S., Germany and Canada are the key producers in the global digital therapeutics market space.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Key Strategies, By Key Players 4.2. Regulatory Landscape 4.3. Reimbursement Scenario 4.4. Collaboration between pharma & providers 4.5. PESTEL Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Outlook 5.1.3. Global Digital Health Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rising prevalence of chronic diseases 5.2.2. Technological Advancements 5.2.3. Rising adoption of telehealth 5.2.4. Cost-effectiveness 5.2.5. Supportive rules and regulations 5.2.6. Rise in demand for digital therapeutics 5.2.7. Strategic Mergers and Acquisitions 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID19 Crisis Analysis 6.1. COVID19 and Impact Analysis 6.1.1. By Solution 6.1.2. By Application 6.1.3. By Indication 6.1.4. By Country 6.2. 2021 Market Scenario 7. Global Market Demand (in Value or Size in US$ Bn) Analysis 2017-2021 and Forecast, 2022–2032 7.1. Historical Market Value (US$ Bn) Analysis, 2017-2021 7.2. Current and Future Market Value (US$ Bn) Projections, 2022–2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2017-2021 and Forecast 2022–2032, By Solution 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Bn) Analysis By Solution, 2017-2021 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Solution, 2022–2032 8.3.1. Monotherapy 8.3.2. Combination Therapy 8.4. Market Attractiveness Analysis By Solution 9. Global Market Analysis 2017-2021 and Forecast 2022–2032, By Application 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Bn) Analysis, By Application, 2017-2021 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Application, 2022–2032 9.3.1. Prevention 9.3.2. Management 9.3.3. Treatment 9.4. Market Attractiveness Analysis By Application 10. Global Market Analysis 2017-2021 and Forecast 2022–2032, By Indication 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2017-2021 10.3. Current and Future Market Size (US$ Bn) Analysis Forecast By Indication, 2022–2032 10.3.1. Diabetes 10.3.2. Obesity 10.3.3. Gastrointestinal Disorders 10.3.4. Cardiovascular Disease 10.3.5. Central Nervous Systems 10.3.6. Others 10.4. Market Attractiveness Analysis By Indication 11. Global Market Analysis 2017-2021 and Forecast 2022–2032, By Business Model 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Bn) Analysis, By Business Model, 2017-2021 11.3. Current and Future Market Size (US$ Bn) Analysis Forecast By Business Model, 2022–2032 11.3.1. Direct to consumer 11.3.2. Fee-for-service 11.4. Market Attractiveness Analysis By Business Model 12. Global Market Analysis 2017-2021 and Forecast 2022–2032, By Region 12.1. Introduction 12.2. Historical Market Size (US$ Bn) Analysis By Region, 2017-2021 12.3. Current and Future Market Value (US$ Bn) Projections, 2022–2032 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2017-2021 and Forecast 2022–2032 13.1. Introduction 13.2. Historical Market Size (US$ Bn) Analysis Trend Analysis By Market Taxonomy, 2017-2021 13.3. Current and Future Market Value (US$ Bn) Projections, 2022–2032 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Solution 13.3.3. By Application 13.3.4. By Indication 13.3.5. By Business Model 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Solution 13.4.3. By Application 13.4.4. By Indication 13.4.5. By Business Model 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. U.S. Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Solution 13.8.1.2.2. By Application 13.8.1.2.3. By Indication 13.8.1.2.4. By Business Model 13.8.2. Canada Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Solution 13.8.2.2.2. By Application 13.8.2.2.3. By Indication 13.8.2.2.4. By Business Model 14. Latin America Market Analysis 2017-2021 and Forecast 2022–2032 14.1. Introduction 14.2. Historical Market Size (US$ Bn) Analysis Trend Analysis By Market Taxonomy, 2017-2021 14.3. Current and Future Market Value (US$ Bn) Projections, 2022–2032 14.3.1. By Country 14.3.1.1. Mexico 14.3.1.2. Brazil 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Solution 14.3.3. By Application 14.3.4. By Indication 14.3.5. By Business Model 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Solution 14.4.3. By Application 14.4.4. By Indication 14.4.5. By Business Model 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. Mexico Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Solution 14.8.1.2.2. By Application 14.8.1.2.3. By Indication 14.8.1.2.4. By Business Model 14.8.2. Brazil Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Solution 14.8.2.2.2. By Application 14.8.2.2.3. By Indication 14.8.2.2.4. By Business Model 14.8.3. Argentina Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Solution 14.8.3.2.2. By Application 14.8.3.2.3. By Indication 14.8.3.2.4. By Business Model 15. Europe Market Analysis 2017-2021 and Forecast 2022–2032 15.1. Introduction 15.2. Historical Market Size (US$ Bn) Analysis Trend Analysis By Market Taxonomy, 2017-2021 15.3. Current and Future Market Value (US$ Bn) Projections, 2022–2032 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Nordic Countries & Russia 15.3.1.8. Rest of Europe 15.3.2. By Solution 15.3.3. By Application 15.3.4. By Indication 15.3.5. By Business Model 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Solution 15.4.3. By Application 15.4.4. By Indication 15.4.5. By Business Model 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. Germany Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Solution 15.8.1.2.2. By Application 15.8.1.2.3. By Indication 15.8.1.2.4. By Business Model 15.8.2. Italy Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. B By Solution 15.8.2.2.2. By Application 15.8.2.2.3. By Indication 15.8.2.2.4. By Business Model 15.8.3. France Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Solution 15.8.3.2.2. By Application 15.8.3.2.3. By Indication 15.8.3.2.4. By Business Model 15.8.4. U.K. Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Solution 15.8.4.2.2. By Application 15.8.4.2.3. By Indication 15.8.4.2.4. By Business Model 15.8.5. Spain Market Analysis 15.8.5.1. Introduction 15.8.5.2. Market Analysis and Forecast by Market Taxonomy 15.8.5.2.1. By Solution 15.8.5.2.2. By Application 15.8.5.2.3. By Indication 15.8.5.2.4. By Business Model 15.8.6. BENELUX Market Analysis 15.8.6.1. Introduction 15.8.6.2. Market Analysis and Forecast by Market Taxonomy 15.8.6.2.1. By Solution 15.8.6.2.2. By Application 15.8.6.2.3. By Indication 15.8.6.2.4. By Business Model 15.8.7. Nordic Countries & Russia Market Analysis 15.8.7.1. Introduction 15.8.7.2. Market Analysis and Forecast by Market Taxonomy 15.8.7.2.1. By Solution 15.8.7.2.2. By Application 15.8.7.2.3. By Indication 15.8.7.2.4. By Business Model 16. East Asia Market Analysis 2017-2021 and Forecast 2022–2032 16.1. Introduction 16.2. Historical Market Size (US$ Bn) Analysis Trend Analysis By Market Taxonomy, 2017-2021 16.3. Current and Future Market Value (US$ Bn) Projections, 2022–2032 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Solution 16.3.3. By Application 16.3.4. By Indication 16.3.5. By Business Model 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Solution 16.4.3. By Application 16.4.4. By Indication 16.4.5. By Business Model 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. China Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Solution 16.8.1.2.2. By Application 16.8.1.2.3. By Indication 16.8.1.2.4. By Business Model 16.8.2. Japan Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Solution 16.8.2.2.2. By Application 16.8.2.2.3. By Indication 16.8.2.2.4. By Business Model 16.8.3. South Korea Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Solution 16.8.3.2.2. By Application 16.8.3.2.3. By Indication 16.8.3.2.4. By Business Model 17. South Asia Market Analysis 2017-2021 and Forecast 2022–2032 17.1. Introduction 17.2. Historical Market Size (US$ Bn) Analysis Trend Analysis By Market Taxonomy, 2017-2021 17.3. Current and Future Market Value (US$ Bn) Projections, 2022–2032 17.3.1. By Country 17.3.1.1. India 17.3.1.2. Indonesia 17.3.1.3. Malaysia 17.3.1.4. Thailand 17.3.1.5. Philippines 17.3.1.6. Vietnam 17.3.1.7. Rest of South Asia 17.3.2. By Solution 17.3.3. By Application 17.3.4. By Indication 17.3.5. By Business Model 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Solution 17.4.3. By Application 17.4.4. By Indication 17.4.5. By Business Model 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. India Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Solution 17.8.1.2.2. By Application 17.8.1.2.3. By Indication 17.8.1.2.4. By Business Model 17.8.2. Indonesia Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Solution 17.8.2.2.2. By Application 17.8.2.2.3. By Indication 17.8.2.2.4. By Business Model 17.8.3. Malaysia Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Solution 17.8.3.2.2. By Application 17.8.3.2.3. By Indication 17.8.3.2.4. By Business Model 17.8.4. Thailand Market Analysis 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast by Market Taxonomy 17.8.4.2.1. By Solution 17.8.4.2.2. By Application 17.8.4.2.3. By Indication 17.8.4.2.4. By Business Model 17.8.5. Philippines Market Analysis 17.8.5.1. Introduction 17.8.5.2. Market Analysis and Forecast by Market Taxonomy 17.8.5.2.1. By Solution 17.8.5.2.2. By Application 17.8.5.2.3. By Indication 17.8.5.2.4. By Business Model 17.8.6. Vietnam Market Analysis 17.8.6.1. Introduction 17.8.6.2. Market Analysis and Forecast by Market Taxonomy 17.8.6.2.1. By Solution 17.8.6.2.2. By Application 17.8.6.2.3. By Indication 17.8.6.2.4. By Business Model 18. Oceania Market 2017-2021 and Forecast 2022-2032 18.1. Introduction 18.2. Historical Market Size (US$ Bn) Analysis Trend Analysis By Market Taxonomy, 2017-2021 18.3. Current and Future Market Value (US$ Bn) Projections, 2022–2032 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Solution 18.3.3. By Application 18.3.4. By Indication 18.3.5. By Business Model 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Solution 18.4.3. By Application 18.4.4. By Indication 18.4.5. By Business Model 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 18.7. Country Level Analysis & Forecast 18.7.1. Australia Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Solution 18.7.1.2.2. By Application 18.7.1.2.3. By Indication 18.7.1.2.4. By Business Model 18.7.2. New Zealand Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Solution 18.7.2.2.2. By Application 18.7.2.2.3. By Indication 18.7.2.2.4. By Business Model 19. Middle East and Africa (MEA) Market Analysis 2017-2021 and Forecast 2022–2032 19.1. Introduction 19.2. Historical Market Size (US$ Bn) Analysis Trend Analysis By Market Taxonomy, 2017-2021 19.3. Current and Future Market Value (US$ Bn) Projections, 2022–2032 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Israel 19.3.1.3. Turkey 19.3.1.4. South Africa & North Africa 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Solution 19.3.3. By Application 19.3.4. By Indication 19.3.5. By Business Model 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Solution 19.4.3. By Application 19.4.4. By Indication 19.4.5. By Business Model 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country Level Analysis & Forecast 19.8.1. GCC Countries Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Solution 19.8.1.2.2. By Application 19.8.1.2.3. By Indication 19.8.1.2.4. By Business Model 19.8.2. Israel Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Solution 19.8.2.2.2. By Application 19.8.2.2.3. By Indication 19.8.2.2.4. By Business Model 19.8.3. Turkey Market Analysis 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Solution 19.8.3.2.2. By Application 19.8.3.2.3. By Indication 19.8.3.2.4. By Business Model 19.8.4. South Africa & North Africa Market Analysis 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast by Market Taxonomy 19.8.4.2.1. By Solution 19.8.4.2.2. By Application 19.8.4.2.3. By Indication 19.8.4.2.4. By Business Model 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players 20.3. Market Presence Analysis 20.3.1. By Regional Footprint of Players 20.3.2. By Channel Footprint of Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. Teladoc Health, Inc. 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Key Financials 21.3.1.4. Sales Footprint 21.3.1.5. SWOT Analysis 21.3.1.6. Strategy Overview 21.3.1.6.1. Marketing Strategy 21.3.1.6.2. Channel Strategy 21.3.2. Click Therapeutics, Inc. 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Key Financials 21.3.2.4. Sales Footprint 21.3.2.5. SWOT Analysis 21.3.2.6. Strategy Overview 21.3.2.6.1. Marketing Strategy 21.3.2.6.2. Channel Strategy 21.3.3. Welldoc 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Key Financials 21.3.3.4. Sales Footprint 21.3.3.5. SWOT Analysis 21.3.3.6. Strategy Overview 21.3.3.6.1. Marketing Strategy 21.3.3.6.2. Channel Strategy 21.3.4. HYGIEIA 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Key Financials 21.3.4.4. Sales Footprint 21.3.4.5. SWOT Analysis 21.3.4.6. Strategy Overview 21.3.4.6.1. Marketing Strategy 21.3.4.6.2. Channel Strategy 21.3.5. DarioHealth Corp 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Key Financials 21.3.5.4. Sales Footprint 21.3.5.5. SWOT Analysis 21.3.5.6. Strategy Overview 21.3.5.6.1. Marketing Strategy 21.3.5.6.2. Channel Strategy 21.3.6. BigHealth 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Key Financials 21.3.6.4. Sales Footprint 21.3.6.5. SWOT Analysis 21.3.6.6. Strategy Overview 21.3.6.6.1. Marketing Strategy 21.3.6.6.2. Channel Strategy 21.3.7. Orexo AB 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Key Financials 21.3.7.4. Sales Footprint 21.3.7.5. SWOT Analysis 21.3.7.6. Strategy Overview 21.3.7.6.1. Marketing Strategy 21.3.7.6.2. Channel Strategy 21.3.8. Akili Interactive Labs, Inc. 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Key Financials 21.3.8.4. Sales Footprint 21.3.8.5. SWOT Analysis 21.3.8.6. Strategy Overview 21.3.8.6.1. Marketing Strategy 21.3.8.6.2. Channel Strategy 21.3.9. Freespira 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Key Financials 21.3.9.4. Sales Footprint 21.3.9.5. SWOT Analysis 21.3.9.6. Strategy Overview 21.3.9.6.1. Marketing Strategy 21.3.9.6.2. Channel Strategy 21.3.10. Voluntis 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Key Financials 21.3.10.4. Sales Footprint 21.3.10.5. SWOT Analysis 21.3.10.6. Strategy Overview 21.3.10.6.1. Marketing Strategy 21.3.10.6.2. Channel Strategy 21.3.11. Kaia Health 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Key Financials 21.3.11.4. Sales Footprint 21.3.11.5. SWOT Analysis 21.3.11.6. Strategy Overview 21.3.11.6.1. Marketing Strategy 21.3.11.6.2. Channel Strategy 21.3.12. Kaiku Health 21.3.12.1. Overview 21.3.12.2. Product Portfolio 21.3.12.3. Key Financials 21.3.12.4. Sales Footprint 21.3.12.5. SWOT Analysis 21.3.12.6. Strategy Overview 21.3.12.6.1. Marketing Strategy 21.3.12.6.2. Channel Strategy 21.3.13. Theranica Bio-Electronics Ltd. 21.3.13.1. Overview 21.3.13.2. Product Portfolio 21.3.13.3. Key Financials 21.3.13.4. Sales Footprint 21.3.13.5. SWOT Analysis 21.3.13.6. Strategy Overview 21.3.13.6.1. Marketing Strategy 21.3.13.6.2. Channel Strategy 21.3.14. Propeller Health 21.3.14.1. Overview 21.3.14.2. Product Portfolio 21.3.14.3. Key Financials 21.3.14.4. Sales Footprint 21.3.14.5. SWOT Analysis 21.3.14.6. Strategy Overview 21.3.14.6.1. Marketing Strategy 21.3.14.6.2. Channel Strategy 21.3.15. Orexo US, Inc. 21.3.15.1. Overview 21.3.15.2. Product Portfolio 21.3.15.3. Key Financials 21.3.15.4. Sales Footprint 21.3.15.5. SWOT Analysis 21.3.15.6. Strategy Overview 21.3.15.6.1. Marketing Strategy 21.3.15.6.2. Channel Strategy 21.3.16. TALi Digital Limited 21.3.16.1. Overview 21.3.16.2. Product Portfolio 21.3.16.3. Key Financials 21.3.16.4. Sales Footprint 21.3.16.5. SWOT Analysis 21.3.16.6. Strategy Overview 21.3.16.6.1. Marketing Strategy 21.3.16.6.2. Channel Strategy 21.3.17. Limbix Health, Inc. 21.3.17.1. Overview 21.3.17.2. Product Portfolio 21.3.17.3. Key Financials 21.3.17.4. Sales Footprint 21.3.17.5. SWOT Analysis 21.3.17.6. Strategy Overview 21.3.17.6.1. Marketing Strategy 21.3.17.6.2. Channel Strategy 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Digital Therapeutics Market
